Diastolic Heart Failure Patients Research Articles

The Relationship of Left Ventricular Function and Plasma Concentration of BNP and NT‐proBNP in Patients with Asymptomatic Diastolic Dysfunction and Diastolic Heart Failure

Objective: to clarify the diagnostic value of Brain Natriuretic Peptide (BNP) and N Terminal-pro BNP (NT-pro BNP), and to investigate their correlations with cardiac function in asymptomatic diastolic dysfunction (ADD) and diastolic heart failure (DHF). Methods: Echocardiography was performed to measure the peak regional myocardial sustained systolic (Sm) and early diastolic velocities (Em), early diastolic flow propagation velocity (Vp), and E wave (E) and A wave (A) of the trans-mitral flow velocities in 166 ADD patients, 153 DHF patients and 77 healthy volunteers. Plasma BNP and NT-pro BNP were examined. Results: Compared to normal volunteers, Sm, Em and Vp decreased (Sm: 9.35±1.88 and 8.79±1.48 vs 10.35±1.41; Em: 9.01±1.97 and 7.62±1.58 vs 10.42±1.81; Vp: 44.00±10.78 and 39.65±11.88 vs 56.31±8.79), and E/Em and E/Vp significantly increased in both ADD and DHF patients. However, the changes in DHF are more significantly than that in ADD. Plasma BNP and NT-pro BNP significantly increased in ADD and DHF patients (BNP: 87.40 and 269.93 vs 58.05; NT-pro BNP: 141.03 and 871.50 vs 63.91). NT-pro BNP is more significantly correlated with Em, E/Em and E/Vp in ADD patients. All above p values <0.05. Conclusions: Plasma BNP and NT-pro BNP were increased, and systolic and diastolic dysfunction was observed in both ADD and DHF. However, these changes were more sever in DHF. NT-proBNP might be used for diagnosis of diastolic dysfunction and identification of ADD patients.

Characterization of Left Ventricular Filling Abnormalities and Its Relation to Elevated Plasma Brain Natriuretic Peptide Level in Acute to Chronic Diastolic Heart Failure

Although Doppler left ventricular (LV) filling abnormalities have been extensively analyzed in patients with systolic heart failure (SHF), they have not yet been well characterized in patients with acute to chronic diastolic heart failure (DHF) in the light of plasma brain natriuretic peptide (BNP) levels. In 25 patients presenting with acute DHF and 25 with acute SHF, echo Doppler parameters and plasma BNP levels were obtained on admission and in the chronic stage. The mitral E/A ratio was lower in DHF patients than in SHF patients in the acute stage (1.3 +/-0.4 vs 1.8+/-0.9, p<0.05), and in the chronic stage of DHF the ratio decreased with plasma BNP level, but plasma BNP level was still greater than 100 pg/ml in 15 patients (60%). Among patients with DHF the plasma BNP level did not correlate with the mitral E/A ratio or deceleration time (r=0,25, p=NS; r=0,23, p=NS), but did with estimated pulmonary artery systolic pressure (r=0.64, p<0.01). A restrictive mitral flow velocity pattern is observed in only 25% of patients with DHF, so it is particularly important to recognize pseudonormalization in those with possible DHF. Persistently elevated plasma BNP level is not primarily caused by LV diastolic dysfunction, but by secondary alteration for hemodynamic adjustment (elevated LV end-diastolic pressure) in patients with DHF.

Systolic and Diastolic Dyssynchrony in Patients With Diastolic Heart Failure and the Effect of Medical Therapy

The purpose of this study was to determine the prevalence of systolic and diastolic dyssynchrony in diastolic heart failure (DHF) patients and identify the effects of medical therapy. The prevalence of systolic and diastolic dyssynchrony in DHF patients is unknown with no data on the effects of medical therapy on dyssynchrony. Patients presenting with DHF (n = 60; 61 +/- 9 years old, 35 women) underwent echocardiographic imaging simultaneous with invasive measurements. An age-matched control group of 35 subjects and 60 patients with systolic heart failure (SHF) were included for comparison. Systolic and diastolic dyssynchrony were assessed by tissue Doppler and defined using mean and SD values in the control group. Systolic dyssynchrony was present in 20 patients (33%) with DHF and 24 patients (40%) with SHF and was associated in both groups with significantly worse left ventricular (LV) systolic and diastolic properties (p < 0.05 vs. control group and patients without systolic dyssynchrony). Diastolic dyssynchrony was present in 35 patients (58%) with DHF and 36 patients (60%) with SHF and had significant inverse correlations with mean wedge pressure and time constant of LV relaxation. In DHF patients, medical therapy resulted in significant shortening of diastolic time delay (39 +/- 23 ms to 28 +/- 20 ms; p = 0.02) but no significant change in systolic interval (p = 0.15). Shortening of diastolic time delay correlated well with tau shortening after therapy (r = 0.85; p < 0.001). Systolic dyssynchrony occurs in 33% of DHF patients, and diastolic dyssynchrony occurs in 58%. Medical therapy results in significant shortening of the diastolic intraventricular time delay which is closely related to improvement in LV relaxation.

Diastolic and Systolic Asynchrony in Patients With Diastolic Heart Failure: A Common But Ignored Condition

The present study aimed to examine whether diastolic and systolic asynchrony exist in diastolic heart failure (DHF) and their prevalence and relationship to systolic heart failure (SHF) patients. Few data exist on mechanical asynchrony in DHF. Tissue Doppler echocardiography was performed in 373 heart failure patients (281 with SHF and 92 with DHF) and 100 normal subjects. Diastolic and systolic asynchrony was determined by measuring the standard deviation of time to peak myocardial systolic (Ts-SD) and peak early diastolic (Te-SD) velocity using a 6-basal, 6-mid-segmental model, respectively. Both heart failure groups had prolonged Te-SD (DHF vs. SHF vs. controls subjects: 32.2 ± 18.0 ms vs. 38.0 ± 25.2 ms vs. 19.5 ± 7.1 ms) and Ts-SD (31.8 ± 17.0 ms vs. 36.7 ± 15.2 ms vs. 17.6 ± 7.9 ms) compared with the control group (all p < 0.001 vs. control subjects). Based on normal values, the DHF group had comparable diastolic (35.9% vs. 43.1%; chi-square = 1.48, p = NS), but less systolic asynchrony than the SHF group (39.1% vs. 56.9%; chi-square = 8.82, p = 0.003). Normal synchrony, isolated systolic, isolated diastolic, and combined asynchrony were observed in 39.1%, 25.0%, 21.7%, and 14.1% of DHF patients, respectively, and these were 25.6%, 31.3%, 17.4%, and 25.6%, correspondingly, in SHF (chi-square = 10.01, p = 0.019). The correlation between systolic and diastolic asynchrony, and between the myocardial velocities and corresponding mechanical asynchrony appeared weak. A wide QRS duration (>120 ms) was rare in DHF (10.9% vs. 37.7% in SHF) (chi-square = 16.69, p < 0.001). Diastolic and/or systolic asynchrony was common in 61% of DHF patients despite narrow QRS complex. The presence of asynchrony was not related to myocardial systolic or diastolic function. Systolic and diastolic asynchrony were not tightly coupled, implying distinct mechanisms.

Outcomes in ambulatory chronic systolic and diastolic heart failure: A propensity score analysis

Prior studies demonstrating significant difference in outcomes in systolic and diastolic heart failure (HF) are often limited to hospitalized acute HF patients, and may be confounded by residual bias. In this analysis, we examined long-term mortality and hospitalization in a propensity score matched cohort of ambulatory chronic systolic and diastolic HF patients. Of the 7788 patients in the Digitalis Investigation Group trial, 6800 had systolic HF (ejection fraction >45%) and 988 had diastolic HF (ejection fraction >45%). We restricted our analysis to 7617 patients without valvular heart disease: 916 diastolic HF and 6701 systolic HF. Propensity scores for diastolic HF, calculated for each patient by a non-parsimonious multivariable logistic regression model, were used to match 697 diastolic HF with 2091 systolic HF patients. Matched Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for outcomes in diastolic (versus systolic) HF. During a median 38-month follow-up, compared with 32% mortality in systolic HF, 23% of diastolic HF patients died (HR=0.70; 95% CI=0.59-0.84; P<.0001). Respective HR (95%CI) for cardiovascular and HF mortality were 0.60 (0.48-0.74; P<.0001) and 0.56 (0.39-0.79; P=.001). All-cause hospitalizations occurred in 64% of systolic and 67% of diastolic HF patients (HR=0.99; 95% CI=0.87-1.11; P=0.801). Respective HR (95%CI) for cardiovascular and HF hospitalizations were 0.84 (0.73-0.96; P=.011) and 0.63 (0.51-0.77; P<.0001). Despite lower mortality and cardiovascular morbidity, diastolic HF patients had similar overall hospitalizations as in systolic HF. Ejection fraction should be assessed in all HF patients to guide therapy, with special attention to non-cardiovascular morbidity in diastolic HF.

Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure

About half of the 5 million heart failure patients in the United States have diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction). Except for candesartan, no drugs have been tested in randomized clinical trials in these patients. Although digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Investigation Group ancillary trial, detailed findings from this important study have not previously been published. Ambulatory chronic heart failure patients (n = 988) with normal sinus rhythm and ejection fraction > 45% (median, 53%) from the United States and Canada (1991 to 1993) were randomly assigned to digoxin (n = 492) or placebo (n = 496). During follow-up with a mean length of 37 months, 102 patients (21%) in the digoxin group and 119 patients (24%) in the placebo group (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.63 to 1.07; P = 0.136) experienced the primary combined outcome of heart failure hospitalization or heart failure mortality. Digoxin had no effect on all-cause or cause-specific mortality or on all-cause or cardiovascular hospitalization. Use of digoxin was associated with a trend toward a reduction in hospitalizations resulting from worsening heart failure (HR, 0.79; 95% CI, 0.59 to 1.04; P = 0.094) but also a trend toward an increase in hospitalizations for unstable angina (HR, 1.37; 95% CI, 0.99 to 1.91; P = 0.061). In ambulatory patients with chronic mild to moderate diastolic heart failure and normal sinus rhythm receiving angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect on natural history end points such as mortality and all-cause or cardiovascular hospitalizations.

The Relationship of a 6-min Walk to V̇O2peak and VT in Older Heart Failure Patients

To evaluate the relationship between a 6-min walk test (6-MWT) to peak oxygen consumption (VO(2 peak)) and ventilatory threshold (VT) in older heart failure (HF) patients, to validate the equation by Cahalin et al., and to develop a new equation to improve the prediction of VO(2 peak) from 6-MWT. Older patients (>65 yr) with systolic or diastolic HF (N=97) performed an exercise test to peak exertion on an upright bicycle ergometer using an incremental protocol. Gas exchange measures were collected along with continuous electrocardiograph monitoring. 6-MWT was performed on an indoor track at a self-selected pace under standardized conditions. The formula of Cahalin et al. was used to predict VO(2 peak) from 6-MWT, and a new equation was generated from the measured VO(2 peak)-6-MWT relationship from this investigation. The correlation between 6-MWT and measured VO(2 peak) was moderate (r=0.54) with a standard error of estimate (SEE) of 2.48 mL.kg.min. The correlation between 6-MWT and VT was weak (r=0.23), whereas the correlation between VO(2 peak) and VT was strong (r=0.74). Correlations between the measured and predicted VO(2 peak) values were moderate (r=0.54) for both prediction equations, and the SEE was 2.83 versus 1.34 mL.kg.min for the Cahalin et al. and the new equation, respectively. These results indicate that 6-MWT does not accurately predict functional capacity in older HF patients, and questions the validity of using this test to determine functional capacity in older HF patients. Predicting VO(2 peak) from equations using 6-MWT also results in substantial variability and, consequently, should not be used in older HF patients where an accurate determination of functional capacity is essential.

Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods

Non-potassium-sparing diuretics are commonly used in heart failure (HF). They activate the neurohormonal system, and are potentially harmful. Yet, the long-term effects of chronic diuretic use in HF are largely unknown. We retrospectively analysed the Digitalis Investigation Group (DIG) data to determine the effects of diuretics on HF outcomes. Propensity scores for diuretic use were calculated for each of the 7788 DIG participants using a non-parsimonious multivariable logistic regression model, and were used to match 1391 (81%) no-diuretic patients with 1391 diuretic patients. Effects of diuretics on mortality and hospitalization at 40 months of median follow-up were assessed using matched Cox regression models. All-cause mortality was 21% for no-diuretic patients and 29% for diuretic patients [hazard ratio (HR) 1.31; 95% confidence interval (CI) 1.11-1.55; P = 0.002]. HF hospitalizations occurred in 18% of no-diuretic patients and 23% of diuretic patients (HR 1.37; 95% CI 1.13-1.65; P = 0.001). Chronic diuretic use was associated with increased long-term mortality and hospitalizations in a wide spectrum of ambulatory chronic systolic and diastolic HF patients. The findings of the current study challenge the wisdom of routine chronic use of diuretics in HF patients who are asymptomatic or minimally symptomatic without fluid retention, and are on complete neurohormonal blockade. These findings, based on a non-randomized design, need to be further studied in randomized trials.

Body composition and echocardiographic abnormalities associated to anemia and volume overload in heart failure patients

Heart failure (HF) patients with hemodilutional anemia had a worse prognosis than those with true anemia. Volume overload (VO) in anemic patients must be identified in order to select the best treatment. We assessed the prevalence of anemia and VO in systolic and diastolic HF patients, and its effects on clinical status, body composition, and quality of life (QOL). Anemia was defined according to the OMS criteria and VO was assessed by bioelectrical impedance analysis (BIA). Echocardiography variables were also obtained. We studied 132 HF patients, 59.1% with systolic and 40.9% with diastolic HF. Anemia was present in 29.5% patients with systolic and 24.1% with diastolic HF (P=0.7). Anemic patients in the systolic HF group tend to be worse functional class than the non-anemic subjects; moreover, in both groups of cardiac dysfunction, the anemic patients had less grip strength, lower body mass index (BMI) and waist and hip circumferences, and a higher percentage of extracellular water (ECW), a higher proportion of patients with total serum cholesterol concentration below the 25th percentile, and a lower serum albumin. When patients were divided in 4 subgroups according to the presence of anemia and/or VO, we observed that VO affected the body composition not only through lower BMI, and waist and hip circumferences but also through a lower phase angle. Systolic HF patients with anemia and VO had the highest dimension of left atrium and pulmonary artery pressure (PAP) levels. Anemia is common in HF and its prevalence is similar in systolic and diastolic HF patients. Anemia was associated to VO, less grip strength and body composition abnormalities; however, VO was related to more severe body composition and echocardiographic abnormalities, as well as to an impairment of QOL. So that, it is important to differentiate between those who have anemia associated to VO and those who have true anemia.

Comparison of VE/VCO2 Slope in Older Systolic and Diastolic Heart Failure Patients and Age-Matched Healthy Controls

Oxygen consumption (VO2) has previously been used for prognosis and risk stratification in patients with heart failure. Furthermore, it has been reported that there is no difference in peak oxygen consumption between systolic and diastolic heart failure patients. More recent research has introduced VE/VCO2 slope as a prognostic measure, but these reports have been limited to systolic heart failure patients only. Risk of mortality has been shown to increase when VE/VCO2 slope values are greater than 34. PURPOSE: To cross-sectionally examine VE/VCO2 slope in systolic and diastolic heart failure populations as well as age-matched healthy controls. METHODS: Symptom limited graded exercise tests were conducted on 147 patients (59 diastolic heart failure, 60 systolic heart failure, 28 controls) using a bicycle ergometer protocol that started at 12 watts and progressed to 25 watts after two minutes. The stages continued to increase by 25 watt increments every three minutes until maximal effort was achieved. Breath-by-breath expired gas analysis was performed using a commercially available system with on-line computer calculations. VE/VCO2 slope was calculated from a regression line of minute ventilation and carbon dioxide production. One way analysis of variance with a Bonferroni post hoc test and Pearson correlations were used for statistical analysis. RESULTS: VE/VCO2 slope was significantly higher in systolic heart failure patients when compared to both diastolic heart failure patients (37.3 ± 7.5 vs. 34.1 ± 6.5, p=0.03) and controls (37.3 ± 7.5 vs. 32.1 ± 4.6, p=0.002). No significant difference was observed between diastolic heart failure and healthy controls (34.1 ± 6.5 vs. 32.1 ± 4.6, p=0.52). Furthermore, we observed that 45% of DHF and 59% had a VE/VCO2 slope greater than 34. Additional analysis resulted in significant correlations between VO2 and VE/VCO2 slope in systolic heart failure patients (r=−0.40, p=0.002), however, there was no significant relationship in diastolic heart failure patients (r=−0.09, p=0.49) or in controls (r=0.13, p=0.50). CONCLUSION: VE/VCO2 slope is significantly higher in patients with systolic heart failure compared to diastolic heart failure and healthy controls. While this study did not address prognosis, the findings are consistent with the belief that mortality rates are greater in SHF than DHF, and VE/VCO2 slope is useful in predicting this risk.

The relationship of six-minute walk distance to VO2peak and VT after exercise training in elderly diastolic heart failure patients

The relationship of six-minute walk distance to VO2peak and VT after exercise training in elderly diastolic heart failure patients

Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure

To support the clinical distinction between systolic heart failure (SHF) and diastolic heart failure (DHF), left ventricular (LV) myocardial structure and function were compared in LV endomyocardial biopsy samples of patients with systolic and diastolic heart failure. Patients hospitalized for worsening heart failure were classified as having SHF (n=22; LV ejection fraction (EF) 34+/-2%) or DHF (n=22; LVEF 62+/-2%). No patient had coronary artery disease or biopsy evidence of infiltrative or inflammatory myocardial disease. More DHF patients had a history of arterial hypertension and were obese. Biopsy samples were analyzed with histomorphometry and electron microscopy. Single cardiomyocytes were isolated from the samples, stretched to a sarcomere length of 2.2 microm to measure passive force (Fpassive), and activated with calcium-containing solutions to measure total force. Cardiomyocyte diameter was higher in DHF (20.3+/-0.6 versus 15.1+/-0.4 microm, P<0.001), but collagen volume fraction was equally elevated. Myofibrillar density was lower in SHF (36+/-2% versus 46+/-2%, P<0.001). Cardiomyocytes of DHF patients had higher Fpassive (7.1+/-0.6 versus 5.3+/-0.3 kN/m2; P<0.01), but their total force was comparable. After administration of protein kinase A to the cardiomyocytes, the drop in Fpassive was larger (P<0.01) in DHF than in SHF. LV myocardial structure and function differ in SHF and DHF because of distinct cardiomyocyte abnormalities. These findings support the clinical separation of heart failure patients into SHF and DHF phenotypes.

Understanding Diastolic Heart Failure With Preserved Ejection Fraction

Congestive heart failure (HF) is a frequent reason for hospital admission. Fifty percent of HF hospitalizations have normal ejection fraction (EF), 1 referred to as diastolic HF (DHF). In contrast, patients with systolic HF (SHF) have reduced EF. The DHF phenotype describes patients with signs and symptoms of HF, normal EF, normal left ventricular (LV) volume, hypertension with increased relative wall thickness, LV diastolic dysfunction, and predominantly elderly women. 1,2 Etiology of DHF Longstanding hypertension may result in significant myocardial hypertrophy, appearance of a smaller ventricular chamber, increased ventricular stiffness, and delayed relaxation. Increased ventricular stiffness requires increased pressure to maintain normal filling in the presence of normal or reduced chamber volume.3 Although DHF has not been studied as extensively as SHF, limited data obtained from patients hospitalized for DHF suggest that demographic characteristics, comorbidities, and pathology differ from those with SHF. Despite these differences, DHF is similar to SHF with regard to volume overload, reduced exercise capacity, impaired quality of life, and long-term mortality.1

Left Ventricular Diastolic Dysfunction in Diabetic Patients

Patients with signs and symptoms of heart failure and a preserved left ventricular (LV) systolic function may have significant abnormalities in diastolic function. This condition is called diastolic heart failure (DHF) and is observed in about 40% of patients with chronic heart failure (CHF). Diabetes mellitus is one of the major risk factors for DHF. Diastolic dysfunction is observed in about 40% of patients with diabetes mellitus and correlates with poor glycemic control. Suggested mechanisms for diastolic dysfunction in the diabetic heart are: (i) abnormalities in high-energy phosphate metabolism; (ii) impaired calcium transport; (iii) interstitial accumulation of advanced glycosylation end products; (iv) imbalance in collagen synthesis and degradation; (v) abnormal microvascular function, (vi) activated cardiac renin-angiotensin system; (vii) decreased adiponectin levels; and (viii) alteration in the metabolism of free fatty acids and glucose. Because most large, randomized clinical trials in CHF have enrolled only patients with systolic dysfunction, the specific management of diastolic dysfunction is largely unknown. The CHARM-Preserved (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity-Preserved) trial, the only mega trial specific for DHF (LV ejection fraction >40%), showed that the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) candesartan cilexetil reduced hospital admissions for CHF but not cardiovascular death. Currently, the pharmacologic treatment used in systolic heart failure is also recommended in DHF and includes administration of diuretics and nitrates for pulmonary congestion, and long-term management with ACE inhibitors, ARBs, aldosterone antagonists, and beta-adrenoceptor antagonists. Poor glycemic control is associated with a high incidence of heart failure in diabetic patients, but the preferable antihyperglycemic regimen for DHF in patients with diabetes mellitus needs to be determined in further studies.

Role of B-type Natriuretic Peptide in Diagnosis and Follow-up of Diastolic Heart Failure

Background and Objectives:Although Doppler echocardiography has been used to identify left ventricular (LV) diastolic dysfunction, its limitations suggest there is a need for new biomarkers to measure the diastolic dysfunction. Because the B-type natriuretic peptide (BNP) levels correlate with the LV diastolic pressure, we hypothesized that the BNP would be useful for diagnosing and monitoring the patients with diastolic heart failure. Subjects and Methods:We prospectively studied a total of 69 consecutive patients (mean age: 68±12 yrs, 31 men and 38 women) who presented to the emergency room with suspected dyspnea of a cardiac origin from November 2003 to May 2004. BNP sampling and Doppler echocardiography were performed for all the study patients. We diagnosed the systolic heart failure (SHF) and diastolic heart failure (DHF) on the conditions that both the clinical and echocardiographic criteria for systolic and diastolic dysfunction were fulfilled. From June 2004 to May 2005, we also performed clinical examinations, measurement of the tissue Doppler derived E/E’ and the BNP level at baseline and at 1 year after pharmacologic treatment for 42 consecutive patients who were diagnosed with DHF in the ER and the outpatient clinic. Results:We diagnosed SHF in 37 patients, DHF in 19 patients and we excluded HF in 13 patients (the control group). The mean BNP levels of the SHF and DHF groups were 716±532 pg/mL and 390±446 pg/mL, respectively, and these values were significantly higher than that of the control group (13±14 pg/mL, p<0.01). The area under the receiver-operating characteristic (ROC) curve for BNP to diagnose DHF was 0.94 (95% CI: 0.86 to 1.02, p<0.001). We also compared the BNP levels with the E/E’ in terms of the changes of the functional status for the 42 patients suffering with DHF. After treatment, the blood pressure (BP) was significantly decreased from 162±26/91±15 to 141±16/80±12 mmHg (p<0.001), the New York Heart Association (NYHA) functional class was decreased from 2.3±0.7 to 1.7±0.6 (p<0.001), and the E/E’ was decreased from 15.9±5.7 to 13.8±5.1 (p<0.01), but there were no significant changes of the BNP levels, from 213±404 to 208±464 pg/mL, following treatment. Conclusion:A BNP assay is clinically useful for diagnosing DHF, and a cut-off value of BNP can be suggested for screening DHF. However, the tissue doppler derived E/E’ is the better index for monitoring changes in the functional status of DHF patients than is the BNP level. (Korean Circulation J 2006;36:359-365)

Importance of Left Ventricular Geometry in the Occurrence of Isolated Diastolic Heart Failure in Patients

Importance of Left Ventricular Geometry in the Occurrence of Isolated Diastolic Heart Failure in Patients

Letter Regarding Article by Baicu et al, “Left Ventricular Systolic Performance, Function, and Contractility in Patients With Diastolic Heart Failure”

To the Editor: This timely article by Baicu et al addresses the controversial topic of patients with diastolic heart failure (DHF), a term currently defined as heart failure in the presence of a normal ejection fraction >50%.1 Forty-seven DHF patients underwent catheterization in association with echocardiography.2 Ten patients who were catheterized had no evidence of cardiovascular disease and served as controls. From their analyses, the authors concluded that a majority of DHF patients displayed left ventricular normal systolic performance, function, and contractility. The article’s Figures 2 and 4 appear to indicate that both endocardial and midwall fractional shortening are load independent. A reevaluation was therefore conducted and yielded the following regression equations: (1) YU=33.4–.0214 XU (n=28, NS (0.11)), (2) YL =32.7–.0600 XL (n=15, NS (0.6)), (3) Ymid=14.9−0.00314 Xmid (n=26, NS (0.76)), and (4) Ymidout=12.8–0.0092 Xmidout (n=15, NS (0.72)). Here, YU versus XU and YL versus XL refer …

Cardiopulmonary Exercise Testing in the Clinical and Prognostic Assessment of Diastolic Heart Failure

This study sought to define the relative prognostic value of cardiopulmonary exercise testing (CPET) variables in heart failure (HF) patients with preserved versus reduced systolic function. Cardiopulmonary exercise testing has an established role in the assessment of patients with systolic heart failure (SHF). Two variables, peak Vo2 and, more recently, the VE/VCO2 slope, have been shown to be extremely valuable in risk stratification. However, data are lacking in terms of the prognostic value of CPET in patients with diastolic heart failure (DHF). A total of 409 HF patients underwent CPET. Patients were divided into three groups according to the following left ventricular ejection fraction (LVEF) cutoffs: > or =40%, > or =45%, and > or =50%. The CPET response and the ability of peak VO2 and the VE/VCO2 slope to predict total mortality and hospitalization were examined. At univariate Cox regression analysis, both the peak VO2 and the VE/VCO2 slope were significant predictors in SHF and DHF. Multivariate analysis documented a similar prognostic power of VE/VCO2 slope and peak VO2 in all SHF groups. Conversely, in DHF patients, VE/VCO2 slope outnumbered peak VO2, remaining the only predictor regardless of LVEF. In DHF, the area under the receiver operating characteristic curve for the VE/VCO2slope identified a cutoff of 32.6 (74% sensitivity, 52% specificity), 33.1 (76% sensitivity, 62% specificity), and 33.3 (97% sensitivity, 40% specificity) for an LVEF cutoff of > or =40%, > or =45%, and > or =50%, respectively. These results extend the clinical and prognostic applicability of CPET to DHF. An impairment in exercise ventilation rather than peak VO2 holds clinical and prognostic impact in this increasing subset of patients.

Relationship of B‐type natriuretic peptide and anemia in patients with and without heart failure: A substudy from the Breathing Not Properly (BNP) Multinational Study

While anemia is a significant risk factor for poor outcomes in patients with heart failure (HF), it is not in defined guidelines for HF assessment. B-type natriuretic peptide (BNP) is a marker for diagnosis and management of patients with HF. We determined the incidence of anemia in patients with HF and the relationship between BNP and hemoglobin (Hgb) levels in patients with and without HF. Results from the Breathing Not Properly Multinational Trial consisted of 1,586 patients presenting to the emergency department (ED) with dyspnea. Because renal insufficiency is a confounding variable for BNP, patients with a creatinine of >or=2.0 mg/dL were excluded. The remaining data were evaluated from 620 non-HF patients (337 M, 283 F) and 547 HF patients (299 M, 248 F). The New York Heart Association (NYHA) HF classification and ejection fraction by echocardiography were assessed for HF patients. Blood was tested for Hgb, BNP, and creatinine. Using World Health Organization criteria for anemia, we observed that HF patients in NYHA class III or IV had lower mean Hgb levels (12.5 g/dL, P < 0.05) and a higher incidence of anemia (48.2%, P < 0.05) than did HF patients in class I or II (13.4 g/dL and 33.9%, respectively). There was no correlation between Hgb and log BNP for females without HF or the aggregate of all HF patients. In contrast, a significant inverse correlation was observed for males without HF (P < 0.001). Although there were differences in the BMI, age, and estimated glomerular filtration rate (eGFR) versus Hgb observed in this group, the log BNP correlation remained significant after multivariate analysis. A significant inverse correlation for log BNP and Hgb were also observed for diastolic (EF >or= 50) HF (P < 0.05) that was also not accounted for by the BMI, age, or eGFR. The presence of anemia is associated with worsening HF at ED presentation. For males without HF and diastolic HF patients of both genders, a low Hgb may be a confounding variable toward increasing BNP. Among systolic HF patients, the presence of a low hemoglobin concentration is not a factor in the interpretation of BNP results.

Association of Diastolic Dysfunction and Outcomes in Ambulatory Older Adults With Chronic Heart Failure

Studies of patients with heart failure and preserved systolic function report variable outcomes compared with those of patients with impaired systolic function. To study outcomes of diastolic (vs systolic) heart failure in older adults with chronic heart failure. Patients were ambulatory chronic heart failure patients 65 years and older (N = 3984) who participated in the Digitalis Investigation Group trial. Of these, 3405 had systolic heart failure (ejection fraction < or =45%) and 579 had diastolic heart failure (ejection fraction >45%). By using a 1:1 match by age, sex, and race, 571 diastolic heart failure patients were matched with 571 systolic heart failure patients. Kaplan-Meier survival analyses and multivariable Cox proportional hazard analyses were used to estimate the risk of various outcomes between the groups. During the 1044 mean days of follow up, compared with 41% of systolic heart failure patients, 27% of diastolic heart failure patients died (p <.001). Presence of diastolic heart failure was independently associated with a 27% decreased risk of all-cause death (adjusted hazard ratio [HR] = 0.73; 95% confidence interval [CI], 0.58-0.91) and a 32% reduction in risk of hospitalization due to heart failure (adjusted HR = 0.68; 95% CI, 0.52-0.88). There was no difference in overall hospitalization between the groups. However, compared with systolic heart failure patients, diastolic heart failure patients were more likely to be hospitalized due to noncardiovascular causes (adjusted HR = 1.38; 95% CI, 1.02-1.88). Older adults with diastolic heart failure had lower risk of all-cause mortality and heart failure-related hospitalizations, but higher risk of noncardiovascular hospitalization.